Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.86 |
| ▸ | MAOB | P27338 | 1/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | LTA4H | P09960 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.50 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177721 | 0.93 | MAOA (1.00) | MAOAMAOBALDH1A1TDP1CYP3A4 | |
| Hydrochloric Acid SCHEMBL11401887 | 0.91 | MAOA (0.95) | MAOAMAOBALDH1A1TDP1CYP3A4 | |
| SCHEMBL9121691 | 0.88 | MAOA (0.64) | MAOAMAOBALDH1A1LTA4HMAPT | |
| SCHEMBL3482671 | 0.88 | ALDH1A1 (0.82) | MAOAMAOBALDH1A1TDP1CYP3A4 | |
| SCHEMBL1271568 | 0.88 | ALDH1A1 (0.82) | MAOAMAOBALDH1A1TDP1CYP3A4 | |
| SCHEMBL12098596 | 0.88 | ALDH1A1 (0.82) | MAOAMAOBALDH1A1TDP1CYP3A4 | |
| SCHEMBL64458 | 0.88 | ALDH1A1 (0.82) | MAOAMAOBALDH1A1TDP1CYP3A4 | |
| SCHEMBL7144807 | 0.88 | ALDH1A1 (0.82) | MAOAMAOBALDH1A1TDP1CYP3A4 | |
| SCHEMBL3482529 | 0.88 | ALDH1A1 (0.82) | MAOAMAOBALDH1A1TDP1CYP3A4 | |
| SCHEMBL8827988 | 0.88 | ALDH1A1 (0.82) | MAOAMAOBALDH1A1TDP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113966324-A | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2022-01-21 | — | — | CN | claimed |
| CN-118994001-A | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-113966324-B | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20220169642-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | CELLESTIA BIOTECH AG (CH) | 2022-06-02 | — | — | US | disclosed |
| US-20220169642-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | CELLESTIA BIOTECH AG (CH) | 2022-06-02 | — | — | US | disclosed |
| CN-113966324-A | NOTCH signaling pathway inhibitors and their use in cancer treatment | 塞莱斯蒂亚生物技术股份公司 | 2022-01-21 | — | — | CN | disclosed |
| WO-2020208139-A1 | INHIBITORS OF NOTCH SIGNALLING PATHWAY AND USE THEREOF IN TREATMENT OF CANCERS | CELLESTIA BIOTECH AG (CH) | 2020-10-15 | — | — | WO | disclosed |
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-13 | — | — | US | disclosed |
| WO-2007092190-A2 | METHODS AND COMPOSITIONS FOR MODULATING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ACTIVITY | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| US-7241812-B2 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241812-B2 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241812-B2 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1781595-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ACTIVITY | Praecis Pharmaceuticals Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060223866-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHARMACEUTICALS, INC. (US) | 2006-10-05 | — | — | US | disclosed |
| US-20060135786-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | PRAECIS PHAMACEUTICALS, INC. (US) | 2006-06-22 | — | — | US | disclosed |
| WO-2006020951-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR ACTIVITY | PRAECIS PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169642-A1 | COMPOUNDS FOR THE TREATMENT OF ONCOVIRUS INDUCED CANCER AND METHODS OF USE THEREOF | NOTCH1, NOTCH4, NOTCH2 | MAOA 4859/4885MAOB 4698/4885ALDH1A1 2833/4885 |
| US-20080064662-A1 | Methods and compositions for modulating sphingosine -1- phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | MAOA 3519/4885MAOB 2920/4885ALDH1A1 3708/4885 |
| US-20060223866-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | MAOA 3519/4885MAOB 2920/4885ALDH1A1 3708/4885 |
| US-20060135786-A1 | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity | S1PR1, S1PR2, S1PR3 | MAOA 3519/4885MAOB 2920/4885ALDH1A1 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.